Healthcare provider profile · identity verified

Huma Khan, MD

Internal Medicine · ROCKLIN, CA · NPI 1922585777

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	321	76
Gabapentin	Gabapentin	190	37
Levothyroxine Sodium	Levothyroxine Sodium	188	42
Amlodipine Besylate	Amlodipine Besylate	185	38
Eliquis	Apixaban	174	28
Furosemide	Furosemide	148	31
Metoprolol Succinate	Metoprolol Succinate	148	34
Lorazepam	Lorazepam	129	43
Metoprolol Tartrate	Metoprolol Tartrate	129	28
Tramadol Hcl	Tramadol Hcl	129	38
Trazodone Hcl	Trazodone Hcl	123	26
Clonazepam	Clonazepam	122	28
Sertraline Hcl	Sertraline Hcl	115	28
Donepezil Hcl	Donepezil Hcl	105	25
Potassium Chloride	Potassium Chloride	105	29
Lisinopril	Lisinopril	104	21
Metformin Hcl	Metformin Hcl	94	24
Pantoprazole Sodium	Pantoprazole Sodium	93	26
Risperidone	Risperidone	90	19
Fluoxetine Hcl	Fluoxetine Hcl	77	suppressed
Levetiracetam	Levetiracetam	77	11
Tamsulosin Hcl	Tamsulosin Hcl	77	20
Escitalopram Oxalate	Escitalopram Oxalate	75	17
Memantine Hcl	Memantine Hcl	74	18
Quetiapine Fumarate	Quetiapine Fumarate	68	25
Losartan Potassium	Losartan Potassium	67	17
Buspirone Hcl	Buspirone Hcl	65	suppressed
Mirtazapine	Mirtazapine	64	13
Hydralazine Hcl	Hydralazine Hcl	60	14
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	57	16
Basaglar Kwikpen U-100	Insulin Glargine,hum.Rec.Anlog	52	suppressed
Famotidine	Famotidine	52	15
Lyumjev Kwikpen U-100	Insulin Lispro-Aabc	52	suppressed
Ipratropium-Albuterol	Ipratropium/Albuterol Sulfate	50	13
Jardiance	Empagliflozin	45	suppressed
Rosuvastatin Calcium	Rosuvastatin Calcium	44	11
Carvedilol	Carvedilol	41	suppressed
Humalog Kwikpen U-100	Insulin Lispro	41	suppressed
Bumetanide	Bumetanide	40	suppressed
Olanzapine	Olanzapine	40	11
Pregabalin	Pregabalin	40	12
Cephalexin	Cephalexin	37	23
Januvia	Sitagliptin Phosphate	37	suppressed
Omeprazole	Omeprazole	37	suppressed
Oxycodone Hcl	Oxycodone Hcl	36	12
Xarelto	Rivaroxaban	36	suppressed
Simvastatin	Simvastatin	35	suppressed
Fluticasone Propionate	Fluticasone Propionate	34	11
Celecoxib	Celecoxib	33	suppressed
Carbidopa-Levodopa	Carbidopa/Levodopa	32	suppressed
Ibuprofen	Ibuprofen	32	suppressed
Ciprofloxacin Hcl	Ciprofloxacin Hcl	31	suppressed
Diazepam	Diazepam	31	suppressed
Midodrine Hcl	Midodrine Hcl	31	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	31	20
Duloxetine Hcl	Duloxetine Hcl	30	suppressed
Finasteride	Finasteride	30	suppressed
Ondansetron Hcl	Ondansetron Hcl	30	suppressed
Allopurinol	Allopurinol	28	suppressed
Aripiprazole	Aripiprazole	28	suppressed
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	28	suppressed
Meclizine Hcl	Meclizine Hcl	28	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	28	suppressed
Warfarin Sodium	Warfarin Sodium	28	suppressed
Farxiga	Dapagliflozin Propanediol	27	suppressed
Citalopram Hbr	Citalopram Hydrobromide	26	suppressed
Tizanidine Hcl	Tizanidine Hcl	25	suppressed
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	24	11
Spironolactone	Spironolactone	24	suppressed
Abrysvo	Rsv Vacc, Pref A And Pref B/Pf	23	23
Lacosamide	Lacosamide	23	suppressed
Myrbetriq	Mirabegron	23	suppressed
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	23	20
Breo Ellipta	Fluticasone/Vilanterol	22	suppressed
Fiasp Flextouch	Insulin Aspart (Niacinamide)	22	suppressed
Latanoprost	Latanoprost	22	suppressed
Alendronate Sodium	Alendronate Sodium	21	suppressed
Alprazolam	Alprazolam	21	suppressed
Clopidogrel	Clopidogrel Bisulfate	21	11
Diltiazem 24hr Er (La)	Diltiazem Hcl	21	suppressed
Toujeo Solostar	Insulin Glargine,hum.Rec.Anlog	21	suppressed
Ezetimibe	Ezetimibe	20	suppressed
Lantus	Insulin Glargine,hum.Rec.Anlog	20	suppressed
Novolog Flexpen	Insulin Aspart	20	suppressed
Albuterol Sulfate	Albuterol Sulfate	19	suppressed
Baclofen	Baclofen	19	suppressed
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	19	suppressed
Torsemide	Torsemide	19	suppressed
Clonidine	Clonidine	18	suppressed
Meloxicam	Meloxicam	18	suppressed
Tradjenta	Linagliptin	18	suppressed
Azithromycin	Azithromycin	17	suppressed
Benztropine Mesylate	Benztropine Mesylate	17	suppressed
Formoterol Fumarate	Formoterol Fumarate	17	suppressed
Methimazole	Methimazole	17	suppressed
Trulicity	Dulaglutide	17	suppressed
Amiodarone Hcl	Amiodarone Hcl	16	suppressed
Budesonide	Budesonide	16	suppressed
Bupropion Xl	Bupropion Hcl	16	suppressed
Clobazam	Clobazam	16	suppressed
Divalproex Sodium	Divalproex Sodium	16	suppressed
Fentanyl	Fentanyl	16	suppressed
Pioglitazone Hcl	Pioglitazone Hcl	16	suppressed
Chlorhexidine Gluconate	Chlorhexidine Gluconate	15	suppressed
Enoxaparin Sodium	Enoxaparin Sodium	15	suppressed
Morphine Sulfate	Morphine Sulfate	15	suppressed
Oxcarbazepine	Oxcarbazepine	15	suppressed
Albuterol Sulfate Hfa	Albuterol Sulfate	14	suppressed
Hydrochlorothiazide	Hydrochlorothiazide	14	suppressed
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	13	suppressed
Prednisone	Prednisone	13	suppressed
Temazepam	Temazepam	13	suppressed
Brimonidine Tartrate	Brimonidine Tartrate	12	suppressed
Mupirocin	Mupirocin	12	suppressed
Nitroglycerin	Nitroglycerin	12	suppressed
Nystatin	Nystatin	12	suppressed
Prednisolone Acetate	Prednisolone Acetate	12	suppressed
Spiriva Respimat	Tiotropium Bromide	12	suppressed
Sulfamethoxazole-Trimethoprim	Sulfamethoxazole/Trimethoprim	12	suppressed
Vilazodone Hcl	Vilazodone Hcl	12	suppressed
Amoxicillin	Amoxicillin	11	suppressed
Anastrozole	Anastrozole	11	suppressed
Cinacalcet Hcl	Cinacalcet Hcl	11	suppressed
Clozapine	Clozapine	11	suppressed
Dorzolamide-Timolol	Dorzolamide Hcl/Timolol Maleat	11	suppressed
Glipizide	Glipizide	11	suppressed
Humalog	Insulin Lispro	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error